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To use survival modeling to estimate disease duration in autosomal dominant familial Alzheimer
disease (ADAD) and ascertain whether factors influencing age at onset also affect survival.
Methods
Symptomatic mutation carriers (201 presenilin 1 [PSEN1] and 55 amyloid precursor protein
[APP]) from ADAD families referred to the Dementia Research Centre, between 1987 and 2019,
were included. Survival was assessed with respect to age at onset, year of birth, APOE e4 status,
cognitive presentation, and sex using multilevel mixed-effects Weibull survival models. The
contribution of mutation and family to variance in age at onset and duration was also assessed.
Results
Estimated mean survival was 11.6 (10.4–12.9) years and was similar for APP and PSEN1 mu-
tations. Sixty-seven percent of the variance in age at onset was explained by mutation and 72% by
mutation and family together. In contrast, only 6% of the variance in disease duration was
explained by mutation specificity and 18% by family membership. Irrespective of gene, survival
appeared longer for successive generations and in individuals with atypical presentations. Older
age at onset was associated with longer duration within PSEN1 and shorter duration within APP
mutation carriers. No differences in survival timewere found between sexes or betweenmutations
located before or beyond codon 200 within PSEN1.
Conclusions
Survival is influenced by mutation to a much lesser extent than age at onset. Survival time has
increased over time and is longer in atypical presentations. These insights may inform the
interpretation of disease-modifying therapy trials in ADAD.
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There are currently no disease-modifying treatments for
Alzheimer disease (AD). Although the search for such
treatments continues, it is relevant to investigate variability
in disease duration and to study factors influencing survival
time.1 Autosomal dominant familial Alzheimer disease
(ADAD) accounts for less than 1% of all AD cases.2
Pathogenic mutations in presenilin 1 (PSEN1),3 presenilin
2,4 or amyloid precursor protein (APP)5 are nearly 100%
penetrant, and age at onset is correlated among family
members.6 This offers a unique opportunity to study sur-
vival after symptom onset relatively precisely. Mean age at
onset tends to be significantly later for APP than PSEN1
mutations,6 and a previous study of our PSEN1 cohort
found that 72% of the variance in age at onset was
explained by the specific mutation and 82% by mutation
and family membership together.7 As in sporadic AD
(particularly in young-onset AD),8 some patients present
atypically with initial symptoms involving cognitive do-
mains other than memory (e.g., language or behavior7,9),
which tend to be more common in PSEN1 compared withh
APP, and particularly in PSEN1 mutations beyond codon
200.7 Given that a considerable amount of the variability in
age at onset can be explained by genetic factors,6 we un-
dertook the current study to investigate the hypothesis
that genetic differences also affect disease duration in
ADAD.
Previous studies have often estimated disease length, in-
cluding only patients who have died, by subtracting an in-
dividual’s age at onset from their age at death. This leads to
an intrinsic bias against longer disease durations as individ-
uals who are affected, but have not yet died, cannot be in-
cluded.10 There have only been a few comprehensive studies
of age at onset and disease course in ADAD, including a
meta-analysis,6,11,12 but none of these used survival models
to account for censoring in date of death in those who did
not die during the follow-up period. Investigations into
generational effects on survival time in ADAD are also
lacking, and survival modeling may offer a useful approach to
evaluate these issues.
The current study addresses differences in survival time
between APP and PSEN1 mutations, APOE e4 carriers and
e4 noncarriers, sexes, cognitive presentations, and PSEN1
mutation position in relation to codon 200. We also evaluate
the extent to which disease duration varies by mutation and
family within each gene and the influence of age at onset and
year of birth on disease duration. We report these differences
in detail while accounting for censoring.
Methods
Study design and participants
We conducted a retrospective cohort study of families with
histories suggestive of ADAD, which were referred to the
Dementia Research Centre at University College London’s
Institute of Neurology (London, United Kingdom) from
clinical and research centers across the United Kingdom and
Ireland between July 1, 1987, and September 2, 2019. We
used clinical and genetic data from these families (table 1).
Inclusion criteria for the study were a family history suggestive
of ADAD and known age at symptom onset. Exclusion criteria
were a neurodegenerative condition other than ADAD, un-
known age at symptom onset, unknown year of birth, and no
information on last year of contact with the center.
Procedures
Contemporaneous records were evaluated to determine age at
onset, defined as the age at which progressive symptoms of
cognitive, behavioral, or motor changes were first noticed by
someone who knew the patient well, and the nature of the
initial symptoms. The cognitive presentation was classified as
either amnestic, for those with initial memory symptoms, or
atypical, for those with nonamnestic initial symptoms such as
behavioral change or symptoms of language or executive dys-
function or dyscalculia. One individual was excluded from the
cognitive presentation analysis as they had a motor pre-
sentation that preceded cognitive symptoms. Age at death was
ascertained from examination of medical records, postmortem
reports, and interviews with living relatives and was collected
up to September 2019. Disease duration was calculated by
subtracting the age at death from the age at onset where this
was available (N = 197), and where this was not available, the
disease duration at censoring was calculated from the age of the
individual at their last assessment (N = 71). One participant
with 2 PSEN1 substitutions (p.Thr291Ala and p.Ala343Thr)
was excluded from the exon analysis because it was unclear
whether pathogenicity was due to one or both of these amino
acid substitutions.7 Twelve additional individuals were ex-
cluded from all analysis: 5 due to uncertainty in year of last
contact (information necessary for censoring) and 7 due to
unknown year of birth (variable considered as a covariate in all
models) (figure e-1, supplementary materials, links.lww.com/
NXG/A312). The intron 4 mutation was classified as involving
exon 4 because it is located just outside this exon.
Mutation analysis was performed as described previously7,13
using Sanger sequencing.APOE e4 status was determined by the
Medical Research Council (MRC) Prion Unit (London, United
Glossary
AD = Alzheimer disease; ADAD = autosomal dominant familial Alzheimer disease; APP = amyloid precursor protein; CI =
confidence interval; ICC = intraclass correlation coefficient; MRC = Medical Research Council; PSEN1 = presenilin 1; TR =
time ratio.
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Kingdom) using minor groove binding probe genotyping assays
(TaqMan, Applied Biosystems). As described in our previous
work, individuals with novel variants in PSEN1 or APP were
assessed for the presence of additional mutations in other
dementia-related genes using the MRC Dementia Gene
Panel.7,14 All novel sequence variants were absent from the
Genome Aggregation Database (gnomad.broadinstitute.org/).
In total, 256 individuals were included in the analyses (201 with
PSEN1 and 55 with APP mutations) (table-e1, supplementary
materials for specific mutations, links.lww.com/NXG/A312).
Statistical analysis
We investigated differences in disease duration between APP
and PSEN1 genes, APOE e4 carriers and e4 noncarriers
within each genetic group, cognitive presentation, sex, exon
number, and position in relation to codon 200 (PSEN1 only)
using the Kaplan-Meier survival estimate for descriptive
statistics and Weibull multilevel parametric survival analysis
(using an accelerated failure time model) to compare the
survival function of different groups of patients and test the
specific hypothesis. Following the second-order relationship
between disease duration and age at onset in Ryman et al.6
meta-analysis, we predefined that we would investigate a
quadratic term for age at onset. We tested the interaction
with gene. Sex, year of birth (range: 1879–1983), and gene
were included as fixed effects and family (as a proxy to
mutation) as random effects in all survival models. The
intraclass correlation coefficient (ICC) was used to quantify
the proportion of variance in disease duration explained by
mutation and family (supplementary materials, links.lww.
com/NXG/A312).
Linear mixed-effects models with random effects for muta-
tion and family and fixed effects for sex, year of birth,
and gene were used to compare differences in age at onset
between genes and cognitive presentations within PSEN1
mutations.
We used p < 0.05 as our measure of statistical significance and
Stata v14 (StataCorp 2015) or later for all analyses. Bonferroni
correction for multiple comparisons was applied for compari-
son of disease duration between exons.
Standard protocol approvals, registrations,
and patient consents
The study was approved by The National Hospital for
Neurology and Neurosurgery and Institute of Neurology
Joint Research Ethics Committee (subsequently, National
Research Ethics Service Committee, London Queen Square,
Research Ethics Committee ref 11/LO/0753). Written in-
formed consent was obtained from all participants or from
their consultee if cognitive impairment prohibited written
informed consent.
Data availability
Anonymized data will be shared by request from any qualified
investigator.
Results
Age at symptom onset was available for all 256 individuals
included (201 with PSEN1 and 55 withAPPmutations). Age at
death was available for 190 of those individuals (77.0% of the
data set: 147 PSEN1 and 43 APP mutations) (table 1).
Disease duration and age at onset: APP
vs PSEN1
Considering only individuals with known age at death
(which does not take into account censoring) (N = 190), the
mean disease duration was 10.4 years (SD 5.3), range: 2–32
years. Survival analysis (N = 256) revealed a 75% probability
of surviving at least 7 years, 50% of surviving at least 10 years,
25% of surviving at least 14 years, and an estimated mean
duration of 11.6 (10.4–12.9) years. Estimated survival time
was similar between APP and PSEN1 mutation carriers
(table 2, figure 1).
Table 1 PSEN1 and APP: characteristics of our cohort
(N = 256)
APP PSEN1 APP + PSEN1
No. families 12 64 76




Sex (males %) 32 (58.2%) 94 (46.7%) 126 (49.2%)





Amnestic 36 (97.3%) 83 (82.2%) 119 (86.2%)





APOE «4 carrier 7 (22.6%) 36 (37.5%) 43 (33.9%)
APOE 44 1 3 4
APOE 34 6 31 37
APOE 24 0 1 1
APOE «4 noncarrier 24 (77.4%) 60 (62.5%) 84 (66.1%)
APOE 23 3 5 8
APOE 33 21 54 75
APOE 22 0 1 1
Abbreviations: APP = amyloid precursor protein; PSEN1 = presenilin 1.
a One additional individual was subsequently excluded as the motor pre-
sentation preceded cognitive symptoms.
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Considering the cohort as a whole, family membership
explained 18% (ICC 0.18; p < 0.001) of the variability in
disease duration, and mutation specificity explained 6% (ICC
0.06; p = 0.188). In patients with a PSEN1 mutation, 25% of
the variance in disease duration was explained by family
membership (ICC 0.25, p < 0.001) and 10% by a specific
mutation (ICC 0.10, p = 0.129). Data were not analyzed
separately for APP mutations due to small numbers.
In accordance with our previous work,7 age at onset was on
average 7.1 years later for individuals with APP mutations
(mean age 50.6 years [SD 5.6], range 38–63 years) than
those with PSEN1mutations (43.5 years [7.2], range: 30–62
years; p < 0.001) (figure 1) (figure e-2, links.lww.com/
NXG/A312, for age at onset distribution of sample). In
patients with PSEN1mutations, 72% of the variance in age at
onset was explained by mutation (ICC 0.72, p < 0.001).
Mutation and family membership together explained 80% of
the variance in age at symptom onset (ICC 0.80, p < 0.001).
Considering both genes together, 67% of the variance was
explained by mutation and 72% by mutation and family
together.






(95% CI) (y)b TR TR: 95% CI p Value
Genes N = 190 N = 256
APP 11.2 (4.9) 4–23 12.5 (9.7–15.3) Reference
PSEN1 9.7 (5.3) 2–32 11.4 (10.1–12.7) 0.91 0.72–1.17 0.474
Sex N = 190 N = 256
Females 10.0 (5.4) 2–32 11.7 (10.3–13.1) Reference
Males 10.1 (5.2) 2–29 11.6 (10.1–13.1) 0.99 0.86–1.13 0.895
Clinical presentation
PSEN1 and APP N = 87 N = 139
Amnestic 10.9 (5.5) 2–27 11.9 (10.6–13.1) Reference
Atypical 15.5 (7.1) 9–32 17.1 (12.4–21.9) 1.44 1.08–1.93 0.013c
PSEN1 N = 60 N = 102
Amnestic 10.2 (5.4) 2–27 11.2 (9.8–12.6) Reference
Atypical 15.9 (7.4) 9–32 16.7 (12.0–21.5) 1.49 1.11–2.01 0.009c
APOE status
PSEN1 and APP N = 92 N = 127
«4 noncarriers 10.4 (5.2) 2–27 11.3 (9.9–12.7) Reference
«4 carriers 12.8 (6.4) 5–32 13.2 (11.1–15.3) 1.16 0.97–1.39 0.100
PSEN1 N = 69 N = 96
«4 noncarriers 9.4 (4.7) 2–27 10.6 (9.0–12.1) Reference
«4 carriers 12.9 (6.7) 5–32 13.2 (10.8–15.5) 1.24 1.00–1.54 0.046c
APP N = 23 N = 31
«4 noncarriers 12.7 (5.8) 4–23 13.4 (10.3–16.6) Reference
«4 carriers 12.7 (5.6) 6–23 12.6 (8.4–16.9) 0.94 0.65–1.35 0.738
PSEN1: codon 200 N = 147 N = 201
Post 9.9 (5.9) 2–32 11.9 (9.9–14.0) Reference
Pre 9.3 (4.7) 3–27 11.5 (9.3–13.7) 0.96 0.76–1.22 0.746
Abbreviations: APP = amyloid precursor protein; CI = confidence interval; PSEN1 = presenilin 1; TR = time ratio.
TR, 95% CI, and p value encompass the effects of the survival model.
a Disease duration was calculated from individuals with known ages at death only.
b Estimated mean survival included any additional censored data.
c Bold: significant at p < 0.05.
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Although no linear relationship between an individual’s age at
onset and the estimated length of disease course was observed
{time ratio [TR] = 1.00 (95% confidence interval [CI]
0.99–1.01), p = 0.286}, there was an interaction between age at
onset and gene in relation to estimated survival (TR = 1.05
[1.02–1.08], p = 0.001). In PSEN1 mutations, later ages at
onset were associated with longer disease durations (disease
duration increased by 1.8% for every 1-year increase in age at
onset [95% CI 0.3–3.4]). Whereas in APP, later ages at onset
were associated with shorter disease durations (disease dura-
tion decreased by 3.0% for every 1-year increase in age at onset
[95% CI 0.9–4.7]) (figure 1). Like Ryman and colleagues,6 we
detected an “inverted-U” shape relationship between age at
onset and age at death such that patients with early (younger
than 40 years) or late (older than 50 years) onset each had
shorter disease duration than patients with onset in midlife
(40–50 years) irrespective of the gene (χ2 = 6.12, p = 0.047;
considering age at onset as a quadratic term). However, in-
cluding the gene interaction abolished this quadratic associa-
tion (χ2 = 1.33, p = 0.515), indicating that gene membership
may have driven the “inverted-U” shape effect.
Sex and year of birth
Sex did not appear to affect disease duration, either for the cohort
as a whole (table 2) or for genes separately (data not shown).
Irrespective of the gene, an individuals’ year of birth appeared
to influence survival and age at onset, with age at onset being
Figure 1 Symptom onset, age at death, disease duration, and survival probability by gene
(A) Unadjusted Kaplan-Meier survival plots show the estimated survival probability by disease duration for PSEN1 vs APP. The blue line references APP and the red
line PSEN1. Ninety-five percent CIs and number of individuals still alive per disease duration length, by 10 years, by 20 years, and by 30 years, are also shown. (B)
Violin plots show thedistributionof age at symptomonset, at death, anddisease duration for PSEN1vs APP. Dataaremedian (line)withmedian interquartile range
(upper and lower dotted lines). Age at onset: 42 (38–48) years vs 50 (48–55) years; age at death: 52 (46–58) years vs 61 (58–66) years; and disease duration: 8 (6–12)
years vs 10 (8–13) years. “*” indicates significant difference between groups. (C) Scatter plot shows the association between age at symptom onset and age at
death in PSEN1 vs APP. The solid line represents the line of best fit from the survivalmodel, adjusted for sex, year of birth, and clustered by familymembership for
each gene. The shaded area represents 95% CIs. Markers show the unadjusted raw data: hollow blue triangles represent individuals with APP mutations and
hollow red circle markers individuals with PSEN1 mutations. APP = amyloid precursor protein; CI = confidence interval; PSEN1 = presenilin 1.
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earlier and duration longer in more recent times. Disease du-
ration increased by 0.6 (95%CI 0.2–1.0)% for every increase in
1 year of birth (p = 0.003). This was also the case when con-
sidering genes separately. Further analysis revealed that the
greatest difference in survival time was between individuals
born before and after 1931: estimated survival: 9.1 (7.7–10.4)
years vs 12.2 (10.8–13.5) years (figure 2). Age at onset de-
creased by 0.04 (0.01–0.07) years for every increase in 1 year of
birth (p = 0.004). Comparing individuals born before or after
the 1930s, we found that the average age at onset was 45.5
(43.3–47.7) years vs 44.6 (42.7–46.5) years, respectively (es-
timated difference = 0.9 [−2.1 to 0.4] years, p = 0.181). The
significantly longer survival time for later generations remained
after adjusting for age at onset (0.6 [0.2–1.0] % increase in
survival for every increase in 1 year of birth; survival estimates
pre vs post births in the 1930s: 8.9 [7.6–10.3] years vs 12.2
[10.9–13.5] years).
Clinical presentation
The PSEN1 subgroup with atypical cognitive presentations
had, on average, a somewhat older age at onset than those with
PSEN1 carriers with amnestic presentations (amnestic: 42.4
years [SD 7.3)] range: 30–62 years vs atypical: 45.4 years [5.7],
range: 38–58 years), but there was little evidence to support
this difference, p = 0.592) (figure e-3, supplementary materials,
links.lww.com/NXG/A312). Within the PSEN1 group, indi-
viduals with atypical presentations had a 49.2% longer survival
time compared with those with amnestic presentations (table 2
and figure 3). Only 8% of the variance in survival time between
individuals with the same cognitive presentations in PSEN1
mutations was explained by family membership (ICC 0.08, p =
0.157). The difference in estimated survival time between
cognitive presentations was replicated combining APP and
PSEN1 groups together (table 2). We did not find any inter-
actions between the cognitive presentation and codon 200
position, APOE e4 status, or age at onset (data not shown).
Similar results emerged when we included age at onset as a
covariate in the model.
APOE «4 status
APOE e4 status did not have an effect on age at onset in our
cohort (mean [95%CI]: e4 carriers = 44.0 [41.8–46.1] years vs
e4 noncarriers = 44.5 [42.5–46.5], p = 0.495). Considering
PSEN1 and APP mutation carriers together, survival analysis
(N = 127) revealed similar estimates between e4 carriers and
e4 noncarriers (table 2).
There was no interaction between APOE e4 status and gene
(TR = 1.35 [0.87–2.08], p = 0.180). Nonetheless, further
analysis revealed an effect seemingly restricted to PSEN1 mu-
tations (N = 96): there was some evidence that e4 carriers had
longer survival time compared with e4 noncarriers (table 2).
APOE e4 status did not have an effect on disease duration in the
small group of individuals with APPmutations (N = 31) (table
2) (figure e-5, supplementary materials, links.lww.com/NXG/
A312). We then examined APOE e4 heterozygous and ho-
mozygous groups separately. Because of statistical power
limitations for homozygous carriers (N = 4), we report het-
erozygous e4 carrier results only (N = 38). In the whole cohort,
there was a trend toward carriers of 1 e4 allele having a 20%
longer survival time compared with e4 noncarriers (13.7
[11.3–16.0] years vs 11.4 [10.0–12.9] years, p = 0.056). Within
the PSEN1 cohort, the possession of 1 e4 allele was associated
with a 30% longer survival time (13.7 [11.1–16.3] years vs 10.6
[9.0–12.1] years, p = 0.023). Comparing carriers of 1 e4 allele
with noncarriers in the APP cohort did not reveal any differ-
ences (12.3 [7.4–17.3] years vs 13.5 [10.1–17.0] years, p =
0.677) (figure e-6 and table e-2, supplementary materials, links.
lww.com/NXG/A312). Considering age at onset in these
models did not change results (data not shown).
Figure 2 Survival probability pre- and post-births in the
1930s
Unadjusted Kaplan-Meier survival plot showing survival by disease duration
for individuals born before and after the 1930s. Green references individuals
born by 1930 and orange after 1930. Ninety-five percent CIs and number of
individuals still alive per disease duration length, by 10 years, by 20 years,
and by 30 years, are also shown. CI = confidence interval; DOB = date of birth.
Figure 3 PSEN1: survival probability by clinical presentation
Unadjusted Kaplan-Meier survival plot shows the estimated survival prob-
ability by disease duration for clinical presentations. Ninety-fivepercent CIs
and number of individuals still alive per disease duration length, by 10 years,
by 20 years, and by 30 years, are also shown. Green references individuals
with amnestic presentations and orange individuals with atypical presenta-
tions. CI = confidence interval; PSEN1 = presenilin 1.
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PSEN1 mutation location
Survival time did not differ between individuals with PSEN1
mutations located pre- or post-codon 200 (table 2). Con-
sidering age at onset in these models did not change results
(data not shown). Some individuals with PSEN1mutations in
exon 8 (N = 40) appeared to reach particularly long disease
durations (mean exon 8 duration—in those with known age
at death: 11.3 years [SD 5.9], range: 5–32 years; figure e-4,
supplementary materials, links.lww.com/NXG/A312). After
adjusting for multiple comparisons (28 comparisons: Bon-
ferroni correction), mutations located in exon 8 (N = 58) had
longer survival estimates than in those in exon 11 (N = 6)
(14.0 [10.8–17.2] years vs 6.2 [3.4–9.0] years, p = 0.034).
Fifteen percent of the variability in survival time among those
with a mutation on the same exon was explained by family
membership (ICC 0.15, p = 0.004).
Discussion
In this study, individuals with APPmutations had, on average,
similar estimated survival time to individuals with PSEN1
mutations—despite theAPP group having an age at onset that
was, on average, 7 years later than the average age at onset in
the PSEN1 group. Estimated mean survival for our cohort was
just over a decade. There was, however, great variability in
disease duration for both the PSEN1 (2–32 years) and APP
(4–23 years) groups and unlike age at onset, mutation type,
and family membership explained relatively little of this var-
iance. In this respect, it may be relevant that we found family
membership to account for a slightly larger proportion of
variance in disease duration than mutation type, although
shared environmental factors could also contribute to this
finding. Although longer survival for females compared with
males has been reported in sporadic AD,15 our results do not
provide evidence for sex differences in survival in ADAD,
which affects individuals at a much younger age.
In accordance with Ryman et al.6 meta-analysis, there was a
trend for longer disease duration in individuals with an age at
onset of 40–50 years (compared with <40 years or >50 years).
Looking at PSEN1 and APP mutation carriers separately
suggested that while in PSEN1 mutations, later ages at onset
were associated with longer disease durations, in APP later
ages at onset were associated with shorter disease durations.
Although it is unclear why these differences between APP and
PSEN1 exist, different paths of disease course between genes
may underly this “inverted-U” shape relationship observed
also in other studies.6
Our results indicate that individuals born after 1930 had
longer survival time compared with those born in previous
generations and that age at onset was earlier with more recent
years of birth. These suggest that gradually (with no step
change), onset or recognition of onset has come earlier. This
may likely be due to greater awareness within families, with
onset coming about 2 years earlier over the course of 2
generations (;50 years). Nonetheless, survival has increased
over and above this. As the difference in age at onset between
births before and after 1931 was smaller than the difference in
survival time (0.9 years vs 3.1 years), this increase in survival
time could not solely be explained by earlier awareness of
symptoms. The increase in survival observed over the study
period accords with the fact that care, as well as life expec-
tancy, has improved. Notably, antibiotics would have become
widely available by the time individuals born after the 1930s
were clinically affected.16
Despite phenotypic and pathologic differences reported be-
tween PSEN1 mutations located before and beyond codon
2007,17,18 we,19 like others,17 found that disease duration did
not significantly differ between these mutation groups. Atypical
presentations have been reported to be more common with
PSEN1 mutations beyond codon 200 in our cohort, and the
prevalence of atypical symptoms also differs markedly between
exons, with nonamnestic cognitive presentations and pyramidal
signs particularly common with mutations located in exon 8.7
Findings from the current study suggest that individuals with
exon 8 mutations may also have particularly long disease du-
rations. An intronic polymorphism in PSEN1 between exon 8
and exon 9 has been reported to show a significant association
with late-onset disease.20,21 There may be differences in the
disease process induced by variants located in this region of
PSEN1, which drive later ages at symptom onset, longer disease
durations, and atypical presentations.
Our findings suggest that carrying APOE e4may be associated
with increased survival time in individuals with PSEN1 mu-
tations, but not inAPPmutation carriers. However, this would
need confirmation as we were not able to demonstrate a
significant difference between the 2 genetic groups in the
effect of APOE e4. Of interest, the rare APOE e3 Christchurch
p. Arg136Ser mutation has recently been reported to delay
onset of cognitive symptoms by 3 decades in a carrier of the
Colombian PSEN1 p.Glu280Ala mutation.22,23 These find-
ings could have implications for the role of APOE in the
pathogenesis, treatment, and prevention of AD and highlight
how much remains unknown about the complexities of in-
teractions between different genetic risk factors and their in-
fluence on disease onset and survival. Larger ADAD studies
that consider the full range of APOE genotypes and follow
individuals over time are needed to untangle the multifaceted
effects of the APOE genotype.
Our study has a number of limitations. First, we included
individuals born over a range of 100 years. Although this
brought the strength of allowing us to study generational
effects, it may somewhat limit how much our findings on
average disease durations may be generalized to newly di-
agnosed patients. Although our analysis was adjusted for year
of birth, replication in larger cohorts of more recently di-
agnosed individuals is needed. Second, we were not able to
consider the effects of lifestyle (e.g., exercise) or life course
(e.g., socioeconomic position) factors on survival. Future
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investigations should study the potential influence of lifestyle
elements on survival rates, particularly in light of our finding
that genetic factors contribute relatively little to the variance
in disease duration we observed in our cohort. This is espe-
cially important to better understand the generalizability of
our findings to individuals in other ADAD and sporadic AD
cohorts. Third, cognitive presentations were classified as
atypical on the basis that the initial symptoms did not involve
memory but instead comprised behavioral change, language
impairment, dyscalculia, or executive impairment. Atypical
symptoms are often more difficult to recognize as signs of AD,
leading to a possible underrepresentation of this group.
Nonetheless, it is perhaps noteworthy that the atypical group
had a longer disease duration, despite the possibility that
symptoms may be noticed later, supporting the notion that
there may be biological differences in those with atypical
presentations, which underpin both the atypical presentation
and the longer disease durations. Last, although we have in-
cluded a relatively large number of cases, considering the
rarity of ADAD, the sample size could be considered a limi-
tation and further investigation of survival in larger ADAD
cohorts will be an important direction for future research.
Multiple factors may contribute to phenotypic variability in
ADAD. Characterizing and investigating variability in disease
duration is the first step toward allowing patients and their
families to plan for the future. A deeper understanding of
variability in disease duration and the factors that may influence
survival may also inform the interpretation of disease-
modifying trials and potentially even highlight new avenues
for targeting the disease.
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